Alexion Pharmaceuticals (NASDAQ:ALXN) Receives New Coverage from Analysts at BMO Capital Markets

BMO Capital Markets began coverage on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) in a research note issued to investors on Thursday, BenzingaRatingsTable reports. The brokerage set an “outperform” rating and a $149.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 35.34% from the company’s previous close.

A number of other analysts also recently weighed in on the company. Robert W. Baird set a $165.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 30th. JPMorgan Chase & Co. initiated coverage on Alexion Pharmaceuticals in a research report on Wednesday, July 31st. They issued an “overweight” rating and a $172.00 target price for the company. Stifel Nicolaus restated a “hold” rating on shares of Alexion Pharmaceuticals in a research report on Friday, August 30th. Wedbush initiated coverage on Alexion Pharmaceuticals in a research report on Wednesday, May 22nd. They issued an “outperform” rating and a $173.00 target price for the company. Finally, Piper Jaffray Companies set a $180.00 target price on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $160.44.

NASDAQ:ALXN opened at $110.09 on Thursday. The business has a 50 day moving average of $110.12 and a 200 day moving average of $124.61. The company has a market capitalization of $23.86 billion, a price-to-earnings ratio of 15.53, a PEG ratio of 1.01 and a beta of 1.67. Alexion Pharmaceuticals has a 1-year low of $92.56 and a 1-year high of $141.86. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.51. The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. Alexion Pharmaceuticals’s quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.07 EPS. As a group, sell-side analysts anticipate that Alexion Pharmaceuticals will post 9.03 EPS for the current year.

In other Alexion Pharmaceuticals news, insider Aradhana Sarin sold 578 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $132.00, for a total value of $76,296.00. Following the completion of the sale, the insider now owns 30,201 shares in the company, valued at $3,986,532. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Indrani Lall Franchini sold 4,500 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $132.78, for a total value of $597,510.00. Following the completion of the sale, the executive vice president now owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. Insiders own 4.08% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. CIBC Asset Management Inc increased its stake in shares of Alexion Pharmaceuticals by 14.1% during the second quarter. CIBC Asset Management Inc now owns 60,702 shares of the biopharmaceutical company’s stock valued at $7,951,000 after buying an additional 7,484 shares during the period. FMR LLC increased its stake in shares of Alexion Pharmaceuticals by 10.4% during the first quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock valued at $3,939,729,000 after buying an additional 2,746,055 shares during the period. Origin Asset Management LLP increased its stake in shares of Alexion Pharmaceuticals by 22.3% during the first quarter. Origin Asset Management LLP now owns 105,200 shares of the biopharmaceutical company’s stock valued at $14,221,000 after buying an additional 19,200 shares during the period. GAM Holding AG increased its stake in shares of Alexion Pharmaceuticals by 27.4% during the first quarter. GAM Holding AG now owns 41,160 shares of the biopharmaceutical company’s stock valued at $5,564,000 after buying an additional 8,858 shares during the period. Finally, Rehmann Capital Advisory Group increased its stake in shares of Alexion Pharmaceuticals by 34.5% during the first quarter. Rehmann Capital Advisory Group now owns 2,293 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 588 shares during the period. Hedge funds and other institutional investors own 93.23% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Further Reading: Return on Investment (ROI)

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply